

2013 Analysis of the US Tumor Marker Testing Market: Emerging Opportunities, Supplier Shares, Country Forecasts, Innovative Technologies, and Competitive Landscape

https://marketpublishers.com/r/25B62429FD0EN.html

Date: April 2013 Pages: 620 Price: US\$ 7,760.00 (Single User License) ID: 25B62429FD0EN

Abstracts

Complete report \$8,700. DataPack (test volumes, sales forecasts, supplier shares) \$3,450.

Highlights

Comprehensive 620-page analysis of the US tumor marker testing market.

Major issues pertaining to the US laboratory practice, as well as key economic, regulatory, demographic, social and technological trends with significant market impact during the next ten years.

Mortality statistics and scientific views on the etiology of major types of cancer, e.g., lung, colorectal, breast, prostatic, pancreatic, leukemia, lymphoma, gastrointestinal, bladder, liver, ovarian, testicular, oral, skin and others.

Ten-year test volume and sales forecasts over for 40 tumor marker performed in US hospitals, commercial laboratories and physician offices.

Placements and installed base of automated and semi-automated analyzers used for tumor marker testing.

Current instrumentation technologies and feature comparison of leading analyzers.



Sales and market shares of leading suppliers.

Emerging diagnostic technologies and their potential market applications.

Product development opportunities.

Profiles of current and emerging suppliers, including their sales, market shares, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Business opportunities and strategic recommendations for suppliers.

Contains 620 pages and 103 tables



Contents

INTRODUCTION

WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

- A. Cancer Statistics and Etiology
 - 1. Brest Cancer
 - 2. Lung Cancer
 - 3. Colon and Rectum Cancer
 - 4. Prostate Cancer
 - 5. Stomach Cancer
 - 6. Leukemia
 - 7. Lymphoma
 - 8. Oral Cancer
 - 9. Skin Cancer
 - 10. Uterine Cancer
 - 11. Ovarian Cancer
 - 12. Bladder Cancer
- B. Major Current And Emerging Cancer Diagnostic Tests
 - 1. Introduction
 - 2. Tumor Marker Classification
 - 3. ACTH
 - 4. Alpha-Fetoprotein (AFP)
 - 5. Beta-2 Microglobulin
 - 6. CA 15-3/ 27.29
 - 7. CA 19-9
 - 8. CA-125
 - 9. Calcitonin
 - 10. Carcinoembrionic Antigen (CEA)
 - 11. Estrogen and Progesterone Receptors
 - 12. Ferritin
 - 13. Gastrin
 - 14. Human Chorionic Gonadotropin (HCG)
 - 15. Insulin
 - 16. NSE
 - 17. Occult Blood
 - 18. PAP Smear/HPV
 - 19. Prostatic Acid Phosphatase (PAP)



- 20. Prostate-Specific Antigen (PSA)
- 21. Squamous Cell Carcinoma Antigen (SCC)
- 22. T and B Lymphocytes
- 23. TdT
- 24. Thyroglobulin
- 25. Tissue Polypeptide Antigen (TPA)
- 26. Biochemical Tumor Markers
 - ADA
- **B-Protein**
- PNP
- 5'-Nucleotidase
- 27. Oncogenes
- Abl/abl-bcr
- AIB1
- BCL-2
- BRCA1
- CD44
- C-fos
- C-myb
- C-myc
- CYP-17
- Erb-B
- HPC1
- N-myc
- P40
- P51
- P53
- PIK3CA
- PTI-1
- Ras
- Reg
- Sis
- Src
- 010
- 28. Polypeptide Growth Factors
- Basic Fibroblast Growth Factor
- Beta-TGF
- Cachectin (TNT)
- Calmodulin
- ECFR



Nerve Growth Factor (NGF) Epidermal Growth Factor (EGF) **Ornithine Decarboxylase** Transferrin Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors 31. Lymphokines Alpha-Interferon **B Cell Growth Factors** B Cell Growth Factor (BCGF) Gamma-Interferon Interleukin-1 (IL-1) Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers N-Acetylglucosamine Actin Alpha-Actin **Antineuronal Antibodies** 7B2 B72.3 Bax BCD-F9 BLCA-4 Blood Group Antigens A,B,H CA CA 72-4/TAG-72 CA CA-242 CA-549 CAM CAR-3 Cathepsin-D Chromogranin A and B Cluster 1 Antigen Cluster-5/5A Antigen CTA

CU18

2013 Analysis of the US Tumor Marker Testing Market: Emerging Opportunities, Supplier Shares, Country Forecast...



DR-70 DU-PAN-2 **Endometrial Bleeding Associated Factor** Endostatin **Epithelial Membrane Antigen** Feulgen Hydrolysis Fibronectin FSH (1->3)-L-fucosyltransferase Gastrin-Releasing Peptide (GRP) GDCFP-15 Glucagon Glycoamines H23 Her-2 Human Carcinoma Antigen **HPA** HSP27 Intermediate Filaments Cytokeratins/CK18/Cyfra 21-1 Desmin **Gliofibrillary Acid Protein Neurofilaments** Vimentin KA **Kinases KP16D3** LAI Leukocyte Common Antigen Lewis Antigens Lysophosphatidic Acid (LPA) Ma 695/Ma MABDF3 MAG ME1 Minactivin MN/CA9 MSA Mucin Cancer Antigen (MCA)



Multiple Tumor Suppressor Myosin NEA-130 NMP22 OA-519 **Opiod Peptides** P-glycoprotein Pancreatic Oncofetal Antigen (POA) **Placental Lactogen PR92** Proliferative Index, Ki-67 Px **RB** Inactivation/Deletion Ret SCCL Selectin Sialic Acid Sialyl SSEA-1/SLX **SN10** Somatostatin **TA-90** TABA Tachykinin TAG TPS Troponin Tubulin VCAM VEGF Villen C. Instrumentation Review And Market Needs 1. Abbott AxSYM

- 2. Abbott Architect c4000
- 3. Abbott Architect i2000 Series
- 4. Abbott Architect ci8200 System
- 5. Beckman Coulter UniCel Series
- 6. Beckman Coulter Access
- 7. Binding Site ESP600
- 8. bioMerieux Mini Vidas

2013 Analysis of the US Tumor Marker Testing Market: Emerging Opportunities, Supplier Shares, Country Forecast...



- 9. Carolina Chemistries BioLis 24i
- 10. DiaSorin Liaison
- 11. Horiba ABX Pentra
- 12. Inverness DS2
- 13. J&J Vitros ECi/ECiQ
- 14. J&J Vitros 3600
- 15. J&J Vitros 5600
- 16. Olympus AU5400
- 17. Olympus AU3000i
- 18. Olympus AU2700
- 19. Roche Modular Analytics
- 20. Roche Cobas Integra
- 21. Roche Cobas Integra 400 Plus
- 22. Roche Elecsys
- 23. Roche Cobas c311
- 24. Siemens ADVIA Centaur
- 25. Siemens Dimension
- 26. Siemens Dimension RxL Max
- 27. Siemens Dimension Vista
- 28. Siemens Immulite
- 29. Siemens Stratus
- 30. Tosoh AIA-Series
- 31. Vital Diagnostics ATAC 8000
- 32. Vital Diagnostics Envoy
- D. Current and Emerging Technologies
 - 1. Monoclonal and Polyclonal Antibodies
 - 2. Immunoassays
 - a. Technological Principle
 - b. Radioimmunoassay (RIA)
 - c. Enzyme Immunoassays (EIA)
 - Overview

ELISA

Immunofiltration

Particle-Membrane Capture Immunoassay

- **Enzyme Amplification**
- d. Fluorescent Immunoassays
- e. Luminescence

Chemiluminescence

Bioluminescence



- f. Latex Agglutination
- g. Immunoprecipitation
- h. Affinity Chromatographu
- i. Liposome Flow-Injection Immunoassay
- 3. Molecular Diagnostics
- a. Technology Overview
- b. Amplification Methods
 - PCR
 - DAP-PCR
 - Immuno-PCR
 - QC-PCR
 - CAR
 - DNA
 - HPA
 - LCR
 - NASBA
 - QBR
 - SDA
 - 3 SR, and others
- 4. Chromosome Analysis
 - a. Chronic Myelogenous Leukemia (CML)
 - b. Acute Myeloid Leukemia (AML)
 - c. Acute Lymphoblastic Leukemia (ALL)
 - d. Malignant Lymphomas Lymphoid Malignancies
 - e. Chronic Lymphocytic Leukemia (CLL)
 - f. Solid Cancers
- g. Chromosomal Translocation and Oncogenes
- 5. Artificial Intelligence
- 6. Flow Cytometry
- 7. Two Dimensional Gel Electrophoresis (2-DGE)
- 8. Biosensors
- 9. Competing/Complementing Technologies
- a. CT
- b. MRI
- c. NMR
- d. PET
- e. Photonics Spectroscopy
- E. Personal Testing



U.S.A.

- A. Executive Summary
- B. Business Environment
 - 1. Health Care Expenditures
 - 2. Cost Consciousness
 - 3. Industry Consolidation
 - 4. Managed Care
 - 5. Hospitals
 - 6. Admissions
 - 7. Length of Stay
 - 8. Industry Diversification
 - 9. Physician Demographics
 - 10. Population Aging
 - a. Chronic Illness
 - b. Disease Incidence
 - c. Susceptibility to latrogenesis
 - d. Multiple Illness Cases
 - 11. Laboratory Regulations
- C. Market Structure
 - 1. Centralized Testing
 - a. Hospitals
 - b. Commercial/Private Laboratories
 - 2. POT/Decentralized Testing
 - a. Physician Offices/Group Practices
 - b. Cancer Clinics
 - c. Point-Of-Care Testing
- d. Other Decentralized Testing Locations
- D. Market Size, Growth and Major Suppliers Sales, Instrument Placements and Market Shares

MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Reagent Kits and Test Systems/Panels
- B. Instrumentation
- C. Computers, Software and Automation
- **D.** Auxiliary Products

DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS



ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies
 - 1. Marketing Approaches
 - 2. Product Complexity
 - 3. Customer Preference
 - 4. Established Suppliers
 - 5. Emerging Suppliers
 - 6. Major Types of Distributors
 - 7. Market Segmentation Factor

POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

COMPETITIVE PROFILES

Abbott AdnaGen Applied Gene Technologies Arca Beckman Coulter/Danaher Becton Dickinson Biomedical Diagnostics bioMerieux Bio-Rad Cepheid Correlogic Systems Dako



Decode Diadexus Diagnocure Diasorin **Eiken Chemical** Enterix Enzo Biochem **Epigenomics Exact Sciences** Fujirebio Gen-Probe **Guided Therapeutics** Hologic Ipsogen **Kreatech** Kyowa Medex Life Technologies Mackay Life Sciences Myriad Genetics Nanogen Elitech OncoLab **Otho-Clinical Diagnostics** Panacea Pharmaceuticals Polartechnics Polymedco PreMD Qiagen **Radient Pharmaceuticals** Roche Scienion Sequenom **Siemens Healthcare** Takara Bio **Targeted Diagnostics & Therapeutics** Tosoh Veridex Wako Pure Chemicals Wallac/PE

Zila



APPENDIXES

Appendix I: Major Universities and Research Centers Developing Cancer Diagnostic Technology and Applications

Appendix II: Assumed Currency Exchange Rates



List Of Tables

LIST OF TABLES

Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/ 27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests **Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis** Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Executive Summary Table: U.S., Total Tumor Marker Test Volume and Sales Forecast by Market Segment U.S., Estimated New Cancer Cases and Deaths U.S., Estimated Cancer Death Rates Per 100,000 Population U.S., Laboratories Performing Tumor Marker Tests by Market Segment U.S., Hospital Laboratories Performing Tumor Marker Tests by Bed Size

U.S., Commercial/Private Laboratories Performing Tumor Marker Tests by Annual Test



Volume

- U.S., Physician Office Laboratories Performing Tumor Marker Tests by Practice Size
- U.S., Total Tumor Marker Test Volume Forecast by Market Segment-201
- U.S., All Market Segments Major Tumor Marker Test Volume Forecast
- U.S., Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Test Volume Forecast
- U.S., Physician Offices/Group Practices Major Tumor Marker Test Volume Forecast
- U.S., Cancer Clinics Major Tumor Marker Test Volume Forecast by Test
- U.S., Total Tumor Marker Sales Forecast by Market Segment
- U.S., All Market Segment Major Tumor Marker Sales Forecast by Test
- U.S., Hospital Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Commercial/Private Laboratories Major Tumor Marker Sales Forecast by Test
- U.S., Physician Offices/Group Practices Major Tumor Marker Sales Forecast by Test
- U.S., Cancer Clinics Major Tumor Marker Sales Forecast by Test
- U.S., ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., AFP Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Beta-2 Microglobulin Test Volume And Diagnostics Sales Forecast by Market Segment
- U.S., CA 15-3/ 27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CA 19-9 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CA-125 Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., CEA Test Volume and Diagnostics Sales by Market Segment
- U.S., Chromogranin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Colon-specific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment U.S., Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market
- Segment
- U.S., Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., HCG Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
- U.S., NSE Test Volume and Diagnostics Sales Forecast by Market Segment



U.S., Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment U.S., Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PAP Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., PSA Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., S-100 Protein Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., TDT Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., TPA Test Volume and Diagnostics Sales Forecast by Market Segment

U.S., Total Tumor Marker Sales By Major Supplier

U.S., ACTH Testing Market Diagnostics Sales by Major Supplier

U.S., AFP Testing Market Diagnostics Sales by Major Supplier

U.S., Beta-2 Migroblolulin Testing Market Diagnostics Sales by Major Supplier

U.S., CA 15-3/ 27.29 Testing Market Diagnostics Sales by Major Supplier

U.S., CA 19-9 Testing Market Diagnostics Sales by Major Supplier

U.S., CA 125 Testing Market Diagnostics Sales by Major Supplier

U.S., CEA Testing Market Diagnostics Sales by Major Supplier

U.S., Ferritin Testing Market Diagnostics Sales by Major Supplier

U.S., HCG Testing Market Diagnostics Sales by Major Supplier

U.S., Insulin Testing Market Diagnostics Sales by Major Supplier

U.S., Parathyroid Hormone Testing Market Diagnostics Sales by Major Supplier

U.S., PAP Testing Market Diagnostics Sales by Major Supplier

U.S., Progesterone Receptor Testing Market Diagnostics Sales by Major Supplier

U.S., PSA Testing Market Diagnostics Sales by Major Supplier



I would like to order

 Product name: 2013 Analysis of the US Tumor Marker Testing Market: Emerging Opportunities, Supplier Shares, Country Forecasts, Innovative Technologies, and Competitive Landscape
Product link: <u>https://marketpublishers.com/r/25B62429FD0EN.html</u>
Price: US\$ 7,760.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/25B62429FD0EN.html</u>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name: Last name: Email: Company: Address: City: Zip code: Country: Tel: Fax: Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <u>https://marketpublishers.com/docs/terms.html</u>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970



2013 Analysis of the US Tumor Marker Testing Market: Emerging Opportunities, Supplier Shares, Country Forecast...